New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2013
11:34 EDTCTICCell Therapeutics reports results from Phase 2 pacritinib trials
Cell Therapeutics announced results from an integrated analysis of data from two completed Phase 2 trials of investigational agent pacritinib, a novel, selective, oral JAK2/FLT3 inhibitor, demonstrating the efficacy and safety profile in patients with myelofibrosis whose baseline platelet counts are ≤100,000/uL was comparable to that of patients with baseline platelet counts of >100,000/uL. The Phase 2 data demonstrated clinically meaningful spleen size and patient-reported symptom score reduction in MF patients with low platelets that were treated with pacritinib. Duration of exposure and average dose intensity were also unaffected by starting platelet counts. There were no significant differences observed in efficacy or safety parameters among patients with low platelet counts when compared to patients with higher platelet counts, including no clinically significant treatment-emergent anemia or thrombocytopenia. The analysis supports the planned second Phase 3 trial expected to start this month, known as PERSIST-2, which will evaluate pacritinib in patients with MF with low platelet counts compared to best available therapy, including the approved JAK2 inhibitor ruxolitinib at recommended doses for patients with low platelet counts. The results were presented today by Rami S. Komrokji, M.D., Clinical Director of the Malignant Hematology Department at the Moffitt Cancer Center and Research Institute, Tampa, Fla., during an oral presentation at the 55th American Society of Hematology Annual Meeting and Exposition held December 710 in New Orleans, La.
News For CTIC From The Last 14 Days
Check below for free stories on CTIC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 19, 2014
20:10 EDTCTICCell Therapeutics in pact with DSM Fine Chemicals Austria
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use